Clinical trial NCT03750214: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
Official title: Bio Colposcopy System CIP: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cervical Cancer Screening
Lead sponsor: BIOP Medical
Sponsor class: INDUSTRY
First posted: 2018-11-21
Enrollment: 26
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.

Detailed description: This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.

The Biop Digital Colposcope is intended for magnified viewing of the tissues of the vagina, cervix and external genitalia in order to assist doctors in diagnosing abnormalities such as lesions or cancer, and selecting areas for biopsy. The images from the digital colposcope are to be viewed on a color display. The digital colposcope is intended for use in hospitals, clinics, and doctor's offices.

The Biop Micro Colposcope probe unit is an imaging tool intended to be placed in the vagina for acquisition of images of the cervix. It is intended as an adjunct to the Biop Digital Colposcope. It should NOT be used as a substitute for a thorough colposcopic evaluation. The Biop Micro Colposcope Probe unit is not intended for use on the vulva and vagina.

It is anticipated that it will take approximately 3 months to complete active enrollment. Study duration for each subject is 1-2 days, including screening, enrolment and procedure. The study will be completed when the final study subject has completed the procedure.

1. Performance - to confirm that average image registration error is less than or equal to (≤) 2mm.
2. Safety - to evaluate the safety of the Biop Digital Colposcope in women undergoing cervical colposcopy procedures.

Eligibility criteria: Inclusion Criteria:

* Females, ages 22 to 65 years old
* Referred for colposcopy, following abnormal cervical cytology
* Subject provides signed informed consent

Exclusion Criteria:

* Currently pregnant or nursing
* Currently menstruating
* Currently has intrauterine device (IUD)
* Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera.
* Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system
* HIV-positive status
* Psychological instability, inappropriate attitude or motivation
* Use of any additional experimental drug or device or participation in another clinical study within the past 30 days

Primary outcomes:
measure: Performance
timeFrame: procedure day ± 1 day
measure: frequency and incidence of all Adverse Events
timeFrame: procedure day ± 1 day
Secondary outcomes:
Other outcomes:
measure: Exploratory Endpoint
timeFrame: procedure day ± 1 day
Locations:
Study officials:
affiliation: RMC Israel
name: Ram Eitan, Md.
role: PRINCIPAL_INVESTIGATOR
References: